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REVIEWS 
Cardiovascular Effects of Neuropeptide Y 
Bernard Waeber, Jean-François Aubert, Roger Corder, Dominique Evéquoz, Jürg Nussberger, 
Rolf Gaillard, and Hans R. Brunner 
Neuropeptide Y (NPY) is present in the brain, the adrenal 
medulla, and peripheral sympathetic nerves. This peptide 
is released together with catecholamines during sympa-
thoadrenal activation. It possesses direct vasoconstrictor 
properties that are not dependent on simultaneous 
adrenergic activation. Moreover, it potentiates the vascu-
lar effect of several stimulatory substances and may 
contribute to the modulation of blood pressure responsi-
veness under a number of circumstances. NPY may also 
Neuropeptide Y (NPY) is a 36 amino acid pep-tide first isolated from porcine brain. 1 , 2 It has been found to be widely distributed throughout the central and peripheral ner-
vous system of a variety of mammals including man (for 
review see references 3 - 6 ) . This peptide is co-stored 
with norepinephrine in perivascular nerve fibers. It has 
also been localized to the adrenal medulla. NPY has 
been shown to induce vasoconstriction through a direct 
effect. In addition, it has been recognized to potentiate 
the contractile response evoked by stimulation of a-
adrenoceptors. 
The vasoactive properties of NPY have been exten-
sively studied during the last few years. In the present 
work, we intend to focus on the evidence suggesting a 
role for this newly discovered peptide in the regulation 
of vascular tone. 
CARDIOVASCULAR EFFECTS OF NPY 
Central Effects Several observations support the view 
that NPY may actively participate in the central control 
of blood pressure. It is present in catecholamine-con-
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be indirectly involved in the control of blood pressure 
through regulating the release of hormones with well-es-
tablished actions on the cardiovascular system. Am J 
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taining neurons located in areas physiologically in-
volved in the regulation of the cardiovascular system, 
particularly at the level of the nucleus tractus soli-
tarius.7'8 One group of investigators has shown that in-
traventricular administration of NPY causes in con-
scious as well as in anesthetized rats a hypotension 
accompanied by a bradycardia. 9 , 1 0 This type of hemody-
namic response corresponds to what is expected to occur 
after central injection of a 2-adrenergic agonists. It is 
therefore of interest that brain o^-adrenergic binding 
sites have been reported to increase in the presence of 
NPY. 1 1 It has been suggested that NPY stimulates pre-
synaptic receptors on norepinephrine and/or epineph-
rine nerve terminals, which may enhance the presynap-
tic û^-adrenoceptor function to inhibit norepinephrine 
release. 1 2 The hypotension and bradycardia induced by 
intracisternal and intraventricular administration of 
NPY has however not been observed by all investiga-
tors . 1 3 1 4 NPY may even be responsible in rats for a 
dose-dependent pressor response and a tachycardia. 1 4 
Such effects could be prevented by pretreating intra-
venously with a- and /^-adrenoceptor blocking agents, 
suggesting that the cardiovascular response to centrally 
administered NPY is mediated by an activation of the 
sympathetic nervous system. Microinjection of NPY at a 
large dose into the nucleus tractus solitarius of rats de-
creases blood pressure and heart rate, whereas a pressor 
response can be obtained when a large dose is used. 1 5 It 
is of note that a functional interaction between NPY and 
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norepinephrine seems to exist at the central level, NPY 
potentiating the effect of the catecholamine. 1 5 Further­
more, NPY seems to contribute to the regulation of cen­
tral catecholamine turnover 1 6 and to exert a negative 
feedback inhibitory effect on norepinephrine release at 
the presynaptic level. 1 7 Whether the level of NPY in the 
brain is relevant to the development of some experimen­
tal forms of hypertension remains unclear. Strain- and 
age-related differences in NPY immunoreactivity occur 
in normotensive and genetically hypertensive rats. 1 8 , 1 9 
Concerning the mechanism of action of NPY at the cel­
lular level, little was known until the recent report of a 
NPY-induced inhibition of adenylate cyclase activ­
ity; 2 0 ' 2 1 it is not yet known however if this action is 
common to all the reported effects of NPY. 
Peripheral Actions 
Vascular Distribution NPY has been identified by 
radioimmunochemical and immunocytochemical 
methods in perivascular nerve fibers of various organs, 
for instance at the level of cerebral, renal, coronary, 
mesenteric, and femoral arteries. 3" 6 NPY-containing 
nerve terminals are present with a much higher fre­
quency around arteries than around veins. 2 2 Most of the 
NPY-containing neurons are probably catecholaminer-
gic, as it is possible to reduce the NPY content of perivas­
cular nerve endings by performing either surgical or 
chemical sympathectomy. 2 3" 2 5 
Effects of NPY in Isolated Vascular Preparations NPY 
possesses vasoconstrictor properties in isolated seg­
ments of arteries. 2 6" 2 9 The NPY-evoked contraction of 
vascular smooth muscle cells is not dependent on adre­
nergic mechanisms, as it cannot be antagonized by a-
adrenoceptor blockade. 3 0 , 3 1 However, an important vas­
cular action of NPY appears to be the potentiation of the 
contractile response to norepinephrine 2 6 , 2 8 , 3 2 , 3 3 and in­
deed to nerve stimulation. 2 9 , 3 3 The NPY-mediated en­
hancement of vascular contraction is not limited to nor­
epinephrine. The same effect has been observed with 
histamine, 2 6 , 3 2 but the effect of NPY on the response to 
5-hydroxytryptamine and K + requires clarification. 2 6 , 3 3 
The fact that the potentiating effect of NPY can be ob­
served with different vasoconstrictors suggests a num­
ber of NPY-induced effects beyond the receptor of the 
vascular smooth muscle cell. However, NPY leads to a 
depolarization of the musculature of the rat tail artery, 3 3 
and this effect may account to some extent for the po­
tentiating action. By depolarizing the arterial smooth 
muscle it is indeed possible to increase the contractile 
responses to a variety of constrictor agonists. 3 4 , 3 5 The 
entry of C a 2 + into the vascular smooth muscle cells 
seems to be important, although not absolutely neces­
sary, for attainment of the direct constrictor effect of 
NPY. 3 1 The potentiation of norepinephrine-induced 
vasoconstriction depends probably more on the N a + 
than the C a 2 + influx. 2 8 For this latter effect, an intracel­
lular sequestered C a 2 + pool appears to play a key role. 2 8 
It is relevant in this context that evidence for a NPY-in­
duced inhibition of adenylate cyclase activity has also 
been found in blood vessels. 3 6 Recently, it has also been 
suggested that NPY modulates adrenergic neurotrans­
mission by an endothelium-dependent mechanism. 3 7 
Finally, it has to be stressed that the degree to which pre-
and postjunctional effects of NPY are concerned in the 
process of sympathetic neurotransmission is still un­
clear. There is however good indication to suggest that 
the postjunctional contractile and facilitatory mecha­
nisms prevail upon the prejunctional inhibitory action 
on norepinephrine release. 3 8 
Effects of NPY in the Isolated Blood-Perfused Spleen 
NPY-like immunoreactivity has been detected within 
the adrenergic innervation of spleen tissue. 3 9 , 4 0 Interest­
ingly, the splenic vascular bed, unlike many isolated 
vessels, 2 6 is very sensitive to the direct vasoconstrictor 
action of NPY. 4 1 Moreover, NPY is released into the 
venous drainage by sympathetic nerve stimulation.4 2 
The increase in splenic arterial perfusion pressure 
evoked by electrical stimulation cannot be prevented by 
adrenoceptor antagonists at doses sufficient to abolish 
the response to norepinephrine. 
Effects of NPY in the Isolated Heart and Cultured Atrial 
Cells The presence of NPY has been demonstrated in 
nerve fibers surrounding blood vessels and myo­
cytes. 2 2 , 4 3 In the isolated rabbit heart, NPY has been 
reported to reduce myocardial perfusion together with 
the force of contraction. 4 4 , 4 5 Other studies failed how­
ever to detect a direct action of NPY on the heart mus­
c l e . 4 6 , 4 7 The most striking cardiac effects of NPY ob­
served using in vitro preparations appear to be a 
prejunctional suppression of stimulated norepinephrine 
release 4 7 and a contraction of the coronary vascular 
bed. 4 6 , 4 8 The constrictor effect of NPY is not affected by 
α-adrenoceptor blockade but is likely to depend on ex­
tracellular calcium ions. 4 8 A new insight in the mode of 
action of NPY has emerged recently from studies per­
formed on primary cultures of rat heart atria. 4 9 NPY was 
found to inhibit the stimulation of adenylate cyclase 
activity known to occur during activation of ^-adreno­
ceptors. Pre treatment of the cells with pertussis toxin 
prevented this inhibitory effect. This observation sug­
gests that NPY binds to its receptor at the surface of the 
cell to activate an inhibitory membrane protein called 
Gi, which then turns off the cyclic AMP pathway. 
NPY and the Adrenal Medulla The presence of NPY has 
been established in adrenal medullary ce l l s 5 0 " 5 3 and ad­
renal medullary pheochromocytoma t issue. 5 2 , 5 4 " 5 7 In­
terestingly, the content of NPY in the tumors is gener­
ally increased in comparison with normal adrenals. 
Some pheochromocytoma appear to synthetize and se-
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crete enough of this peptide to raise circulating NPY 
leve l s . 5 4 5 6 5 7 Whether determination of plasma NPY 
levels is of practical use in the diagnosis of pheochro-
mocytoma needs to be further explored. 5 7 It remains 
also a matter of speculation whether the elevation of 
plasma NPY levels found in some patients with 
pheochromocytoma is sufficient to contribute to the hy­
pertensive state. 
A key question is whether NPY is released into the 
circulation upon sympathetic activation. This seems to 
be really the case since both reflex sympathetic activa­
tion and electrical nerve stimulation of the adrenal have 
been shown recently to cause a marked increase in NPY 
and catecholamine output. 5 8 In the intact animal, how­
ever, there is evidence suggesting that the sympathetic 
nerves contribute to the largest extent to the increase in 
plasma NPY concentrations after activation of the sym­
pathoadrenal system. 5 9 In basal conditions, conscious 
normotensive rats exhibit similar circulating levels of 
NPY independently of the presence or the absence of 
adrenal medulla (personal observation). 
Effects of NPY in Intact Animals In pithed rats, NPY 
infusion in a dose that does not affect blood pressure per 
se enhances the pressor response to α j-adrenoceptor 
stimulation with phenylephrine as well as to electrical 
stimulation of the sympathetic outflow. 6 0 In these rats, a 
direct pressor effect of NPY can be obtained by raising 
the dose of the peptide. 6 0 Potentiation of the blood pres­
sure effect of α-adrenoceptor stimulation has also been 
observed in conscious rats infused with a nonpressor 
dose of NPY. 6 1 This was shown utilizing not only nor­
epinephrine, but also the indirectly acting sympathomi­
metic agent tyramine (personal observation). Interest­
ingly, the blood pressure response to angiotensin II was 
also clearly increased by this low dose of NPY which 
given alone was devoid of pressor effects. In contrast, 
NPY did not alter the response to vasopressin. Several 
studies have confirmed that the NPY-induced pressor 
effect is not attenuated by α-adrenoceptor block­
ade. 6 0 " 6 4 
The vasoconstrictor activity of NPY in vivo seems to 
be Ca 2 +-dependent, as it can be reduced by calcium 
entry blockade. 6 0 , 6 2 ' 6 4 It is possible to trigger the release 
of NPY into systemic circulation by splanchnic nerve 
stimulation.65 Evidence has been provided from studies 
in pithed guinea pigs that Clonidine, an a 2-adrenoceptor 
agonist, reduces the increase in plasma NPY concentra­
tion resulting from electrical nerve stimulation.6 6 This 
points to a role of presynaptic a 2-adrenoceptors in the 
modulation of NPY release by nerve terminals. The im­
portance of sympathetic outflow in determining circu­
lating levels of NPY is strongly suggested by the fact that 
the ganglion blocker pentolinium, at the same time as 
reducing blood pressure, markedly reduces in acute ex­
periments the peptide concentration in the plasma. 6 7 
low Na+ normal Na+ high Na+ 
FIGURE 1. Comparison of plasma concentrations of NPY with 
catecholamines in rats kept on low (n = 10), normal (n = 12), and 
high (n = 14) sodium diets. Plasma noradrenaline, adrenaline, 
and NPY concentrations are shown in the left, middle, and right 
columns, respectively, for the three different sodium intakes. The 
NPY concentration was significantly higher (**P < 0.02) in the 
group receiving a high sodium diet when compared to rats on a low 
sodium diet (from reference 75). 
When infused for 30 minutes at a dose lacking any 
effect on systemic pressure, NPY does not modify heart 
rate and cardiac output in conscious rats. Furthermore, it 
does not produce major changes in regional blood flow 
distribution.6 8 In anesthetized rats infused only briefly 
with NPY (2 minutes), blood flow increased in several 
tissues (notably the kidney and the heart) in the absence 
of a generalized effect on hemodynamics. 6 9 A poten­
tially important function of NPY appears to be an inhib­
itory action on the response of the cardiac vagus to sym­
pathetic stimulation. 7 0 ' 7 1 
A number of interesting findings have been obtained 
by studying the relationship between blood pressure 
responsiveness and NPY in states where responses to 
vasoconstrictor agents are altered. Endotoxemia is one 
condition in which vascular responsiveness to pressor 
agonists has been shown to be markedly suppressed, 
both in hypotensive and nonhypotensive states. 7 2 ' 7 3 It is 
therefore noteworthy that NPY infused at a nonpressor 
dose can reverse this abnormality. 6 1 It is perhaps 
through this mechanism that NPY prevents the blood 
pressure fall induced by endotoxin in rats subjected to 
adrenal medullectomy. 7 4 
NPY may also be involved in the modulation of blood 
pressure responsiveness during changes in sodium bal­
ance. 7 5 Thus, circulating levels of NPY were higher in 
rats maintained for 3 weeks on a high sodium intake 
than in animals kept for the same period on a salt-defi­
cient diet. Intermediate values were obtained in rats fed 
with a regular sodium intake (Figure 1). It has to be 
stressed that plasma norepinephrine and epinephrine 
achieved similar levels in the three different study 
groups. Sodium loading is known to enhance blood 
pressure responsiveness to norepinephrine and to favor 
the development of hypertension. It is therefore con­
ceivable that an excess of sodium influences blood pres­
sure regulation to some extent via an increase in circu-
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lating NPY levels, which in turn potentiate the vasocon­
strictor effect of α-adrenoceptor stimulation. 
Some of the cardiovascular effects of NPY may be 
related to an action of the peptide on the secretion of 
hormones physiologically involved in blood pressure 
control. For instance, NPY suppresses renin release, 7 6- 7 7 
most likely by inhibiting adenylate cyclase activity in 
renin-producing cells through a pathway involving the 
protein Gi . 7 7 NPY has also been shown to increase the 
release of the atrial natriuretic factor; 7 8 the significance 
of this finding is less clear but it could lead to diuresis 
and natriuresis. 
Effects of NPY in Man NPY infused intravenously at a 
dose that slightly increases blood pressure is well toler­
ated by normal subjects . 7 9 8 0 Recently, NPY has been 
administered directly into a coronary artery of patients 
with typical angina but no significant abnormality at the 
arteriogram.8 1 Half of the patients developed a transient 
myocardial ischemia during infusion of the peptide. 
Results obtained in man suggest that NPY is released 
together with catecholamines when the sympathoadre­
nal system is activated. This has been shown during 
physical exercise, 8 2" 8 4 in response of the cold pressor 
test, 8 3 as well as during thoracotomy and surgery for 
cardiopulmonary bypass. 8 5 In two studies, 8 2 8 5 there was 
a significant correlation between plasma levels of NPY 
and norepinephrine, but not between plasma levels of 
NPY and epinephrine. This was taken as an indication 
for a release of neural rather than adrenal origin. 
CONCLUSIONS 
Interest in the field of research on NPY has been grow­
ing rapidly during recent years. This peptide is widely 
distributed within the central and peripheral nervous 
system. The property of NPY that seems to be of major 
physiologic importance is the action on vascular smooth 
muscle cells. Indeed, NPY can cause blood vessels to 
constrict through both direct and indirect mechanisms. 
NPY may therefore be implicated in cardiovascular ho­
meostasis by modulating blood pressure responsiveness 
to different pressor stimuli. In addition, there is now 
some evidence suggesting that NPY influences the se­
cretion of hormones known to play a role in body fluid 
and blood pressure control. 
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